1 Food Science and Human Nutrition Department, University of Florida, 572 Newell Drive, Gainesville, FL 32611, USA.
2 Lallemand Health Solutions Inc., 6100 Royalmount, Montréal, QC H4P 2R2, Canada.
Benef Microbes. 2019 May 28;10(5):497-509. doi: 10.3920/BM2018.0151. Epub 2019 May 15.
Microbial metabolism in the gut may alter human bile acid metabolism in a way that beneficially affects lipid homeostasis and therefore cardiovascular disease risk. Deconjugation of bile acids by microbes is thought to be key to this mechanism but has yet to be characterised in blood and stool while observing lipid markers. The aim of this study was to determine the effect of 3 different probiotic strains on plasma and stool bile acids in the context of lipid and glucose metabolism. In this 18-week, randomised, double-blind crossover study, healthy adults (53±8 years) with a high waist circumference underwent a 1-week pre-baseline period and were then randomised to receive 1 capsule/day of R0179 (2.5×10 cfu/capsule; n=39), HA-119 (5×10 cfu/capsule; n=38), subsp. B94 (5×10 cfu/capsule; n=37) or placebo for 6 weeks. Following a 3-week washout and second pre-baseline week, participants were crossed to the other intervention for 6 weeks followed by a 1-week post-intervention period. Blood and stool samples were collected at the beginning and end of each intervention to measure bile acids, serum lipid profiles, and glucose and insulin levels. Data from the placebo intervention were combined for all participants for analyses. In obese participants, the difference (final-baseline) in the sum of deconjugated plasma bile acids was greater with consumption of (691±378 nmol/l, =0.01) and (380±165 nmol/l, =0.04) than with placebo (98±176 nmol/l, n=57). No significant differences were observed for any probiotics for stool bile acids, serum lipids, blood glucose or insulin. These data suggest that and had no effect on glucose metabolism or serum cholesterol but increased deconjugated plasma bile acids in obese individuals. Additional studies should be conducted to confirm these findings and explore potential mechanisms. This trial was registered at clinicaltrials.gov as NCT01879098.
肠道中的微生物代谢可能以一种有益于脂质稳态从而降低心血管疾病风险的方式改变人体胆汁酸代谢。微生物对胆汁酸的去结合作用被认为是这一机制的关键,但在观察脂质标志物的同时,尚未在血液和粪便中对其进行描述。本研究旨在确定 3 种不同益生菌菌株对血脂和葡萄糖代谢背景下的血浆和粪便胆汁酸的影响。在这项为期 18 周、随机、双盲交叉研究中,腰围较大的健康成年人(53±8 岁)进行了为期 1 周的预基线期,然后随机接受 1 天 1 粒 R0179(2.5×10 cfu/胶囊;n=39)、HA-119(5×10 cfu/胶囊;n=38)、subsp. B94(5×10 cfu/胶囊;n=37)或安慰剂治疗 6 周。经过 3 周洗脱期和第二次预基线周后,参与者交叉接受其他干预治疗 6 周,然后进行 1 周的干预后阶段。在每个干预的开始和结束时采集血液和粪便样本,以测量胆汁酸、血清脂质谱以及血糖和胰岛素水平。所有参与者的安慰剂干预数据合并用于分析。在肥胖参与者中,与安慰剂(n=57)相比,消耗 R0179(691±378 nmol/l,=0.01)和 subsp. B94(380±165 nmol/l,=0.04)时,血浆去结合胆汁酸总和的差异(终-基线)更大。对于任何益生菌,粪便胆汁酸、血清脂质、血糖或胰岛素均无显著差异。这些数据表明,R0179 和 subsp. B94 对葡萄糖代谢或血清胆固醇没有影响,但增加了肥胖个体的血浆去结合胆汁酸。应进行更多研究以确认这些发现并探讨潜在机制。该试验在 clinicaltrials.gov 上注册为 NCT01879098。